Ascletis Pharma Inc. disclosed that on 7 July 2026 it repurchased 100,000 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 11.28 and HKD 11.67, for a total consideration of HKD 1.15 million. The shares are intended for cancellation.

Including this latest transaction, Ascletis now holds 9.63 million repurchased shares pending cancellation, equivalent to approximately 0.91% of the company’s 1.06 billion issued shares (excluding treasury shares) as at the same date. The issued share count and treasury stock balance remain unchanged at 1,061.37 million and 7.08 million shares, respectively.

The repurchase forms part of a mandate approved on 29 June 2026 that authorises the company to buy back up to 106.14 million shares. Purchases executed under this mandate to date total 245,000 shares, representing 0.02% of the issued share base at the mandate approval date.

In accordance with Hong Kong listing rules, Ascletis is subject to a moratorium on issuing new shares or disposing of treasury shares until 6 August 2026.